InMode Ltd.
InMode is an Israeli medical technology company that designs, develops, manufactures and markets energy-based aesthetic and medical treatment systems for physicians, including plastic and facial surgeons, aesthetic surgeons, dermatologists and OB/GYNs. Its products support minimally invasive and non-invasive procedures involving face and body contouring, skin rejuvenation, hair reduction and women’s wellness. The systems use radio-frequency energy, laser, intense pulsed light and energy muscle stimulation, with platforms paired with handpieces or hands-free applicators, disposable tips and proprietary software. Brands and platforms include BodyTite, Morpheus8, Optimas, EmpowerRF, EvolveX, Triton, ApexRF and Solaria. InMode sells its platforms and related consumables, and offers physician training and post-sales support. It markets products through a direct sales force and distributors. Its registered office is in Yokneam, Israel.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $INMD in the last 30 days.
See all $INMD insider activity →Baird kept InMode at Neutral but reduced its price target to $15 from $17, an 11.8% cut. The new target suggests 9.2% upside from the Nov 11 close of $13.73, according to the firm.
InMode Ltd. (INMD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 InMode Reports Third Quarter 2026 Financial Results: Quarterly GAAP Revenues of $92.1 Million; Reaffirms Full-Year 2026 Financial Outlook YOKNEAM, Israel, November 11, 2026 - InMode Ltd. (Nasdaq: INMD) (“InMode”) , a leading global provider of innovative medical tech
InMode Ltd. (INMD) reported Q3 2026 revenues of $92.1M, stable year-over-year. GAAP net income was $18.9M ($0.32 per share), down from $21.9M ($0.34 per share) in Q3 2025. Non-GAAP net income was $21.9M ($0.37 per share). The company reaffirmed its full-year 2026 outlook, expecting revenues between $365M and $375M. Cash position was $512.7M as of September 30, 2026.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning INMD (InMode Ltd.). Coverage has been balanced: 1 bullish, 4 neutral, and 1 bearish.
Recent INMD coverage spans earnings, mergers & acquisitions and financial news.
The downgrade suggests potential downside pressure on INMD as analysts reduce expectations.
Earnings release with modest revenue and profit decline; guidance reaffirmed.
Earnings release with modest revenue decline and lower margins may pressure the stock.
The bid creates pressure on InMode shares as the board resists and may lead to a lower price unless the offer is accepted.
Guidance slightly above consensus, likely supportive for the stock.
AlphAI scores every news story that mentions INMD with an AI model for sentiment and relevance, and aggregates insider trades from InMode Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Baird kept InMode at Neutral but reduced its price target to $15 from $17, an 11.8% cut. The new target suggests 9.2% upside from the Nov 11 close of $13.73, according to the firm.
InMode Ltd. (INMD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 InMode Reports Third Quarter 2026 Financial Results: Quarterly GAAP Revenues of $92.1 Million; Reaffirms Full-Year 2026 Financial Outlook YOKNEAM, Israel, November 11, 2026 - InMode Ltd. (Nasdaq: INMD) (“InMode”) , a leading global provider of innovative medical tech
InMode Ltd. (INMD) reported Q3 2026 revenues of $92.1M, stable year-over-year. GAAP net income was $18.9M ($0.32 per share), down from $21.9M ($0.34 per share) in Q3 2025. Non-GAAP net income was $21.9M ($0.37 per share). The company reaffirmed its full-year 2026 outlook, expecting revenues between $365M and $375M. Cash position was $512.7M as of September 30, 2026.
Steel Partners Holdings L.P. set an October 30, 2026 expiration for its $16.75 per share all-cash offer for InMode Ltd. The company accuses InMode's board of breaching fiduciary duties and demands engagement. InMode has not provided diligence materials or engaged in good faith, according to Steel.
InMode (INMD) anticipates Q3 2026 revenue of $91.8M-$92M, with full-year revenue projected at $365M-$375M. The consensus estimates are $91.59M for Q3 and $370.27M for the year, according to the company's press release.
InMode Ltd. reported preliminary Q3 2026 revenue of $91.8M-$92.0M and reaffirmed full-year guidance of $365M-$375M. The company will not hold an earnings call due to a strategic proposal review by its special committee. Final results will be released on November 11, 2026, and may differ from preliminary figures.
InMode Ltd. (INMD) launched Morpheus8 Cool, an advanced RF microneedling technology with enhanced comfort and control. The new handpiece features Cool Comfort Technology and an interactive user interface. The company reports high demand and positive feedback from providers.
InMode Ltd. (Nasdaq: INMD) reported Q2 2026 GAAP revenues of $95.6M, unchanged vs Q2 2025. Consumables and service rose 13% to $22.3M. GAAP net income was $17.1M ($0.29/diluted share). Cash and equivalents plus marketable securities totaled $501.1M at June 30, 2026. FY2026 outlook: revenues $365M-$375M and non-GAAP EPS $1.29-$1.34.
InMode Ltd. (INMD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025 YOKNEAM, Israel, August 5, 2026 - InMode Ltd. (Nasdaq: INMD) (“InMode”) , a leading global provider of innovative medical techno
InMode Ltd. (NASDAQ: INMD) said its board received an unsolicited acquisition proposal from Steel Partners Holdings L.P., dated July 9, 2026. A special committee of independent directors will review the proposal with legal and financial advisors. The committee said it will not comment further for now.
